Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SQLE | Q14534 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MC1R | Q01726 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3252892 | 1.00 | LMNA (0.47) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3256688 | 0.88 | LMNA (0.60) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL30960251 | 0.88 | LMNA (0.60) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL30960258 | 0.88 | LMNA (0.60) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3256682 | 0.88 | LMNA (0.60) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3251189 | 0.84 | LMNA (0.46) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3251198 | 0.84 | LMNA (0.46) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL17227620 | 0.82 | LMNA (0.43) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3256605 | 0.78 | CYP2D6 (0.78) | LMNAADRA2ACYP2D6SLC6A2SQLE | |
| SCHEMBL3256599 | 0.78 | CYP2D6 (0.78) | LMNAADRA2ACYP2D6SLC6A2SQLE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261874-B1 | SPECIFIC MONOCLONAL ANTIBODY AGAINST TERBINAFINE | NOVARTIS AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-7122184-B2 | Specific monoclonal antibody against terbinafine | NOVARTIS AG (CH) | 2006-10-17 | — | — | US | disclosed |
| US-20030087323-A1 | Specific monoclonal antibody against terbinafine | NOVARTIS AG (CH) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087323-A1 | Specific monoclonal antibody against terbinafine | NEFM, CD69, PBK | LMNA 3411/4885ADRA2A 4722/4885CYP2D6 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.